End of Treatment Sample Clauses

End of Treatment. (Visit 17 or Withdrawal from Study) The end of treatment for subjects completing the study is Visit 17. End of treatment testing will also be performed for subjects who are withdrawn from treatment prior to completion of the study at the time of their treatment termination. For subjects who withdraw from the study prior to completion, the site will also attempt to contact the subject at or about the 56-week time point to obtain a weight measurement, waist circumference, blood chemistry panel and xxxxx xxxxx. Activities at the end of treatment visit include: · Obtain weight and waist circumference measurements; · Obtain xxxxx xxxxx; *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. · Assess adverse events (including eye symptoms), if any; · Assess concomitant medications; · Administer ***; · Collect urine sample for pregnancy test (females of childbearing potential only) and perform pregnancy test; · Administer ***; · Administer *** and ***; · Perform *** scan ***; · Administer *** for *** and ***; · Complete End of Treatment Questions: ***; · Obtain fasting blood and urine samples for laboratory testing; · Obtain samples for biomarkers: C-reactive protein (blood), HgbA1c (blood), microalbumin (urine) and creatinine (urine); · Perform complete physical examination (including neurological examination and auscultation for heart sounds); · Perform 12-lead electrocardiogram; · Collect study medications dispensed at previous visit, assess treatment compliance and perform drug accountability;
Sample 1
AutoNDA by SimpleDocs
End of Treatment. Patients will continue to receive study drug until they present with PD per RECIST 1.1, as assessed by study Investigator, unacceptable toxicity, withdraw consent, or death, whichever comes first, or until the Sponsor terminates the study. Study treatment and/or participation in the study may be discontinued at any time at the discretion of the Investigator. The following may be reasons for the Investigator to remove a patient from the study drug: • The patient suffers an intolerable AE • Noncompliance, including failure to appear at one or more study visits • The patient was erroneously included in the study The reason for treatment discontinuation must be captured in the EOT electronic case report form (eCRF). Any AEs experienced up to the point of discontinuation and 30 days thereafter must be documented on the AE eCRF. All serious adverse events (SAEs), and those AEs assessed by the Investigator as at least possibly related to study drug should continue to be followed until they resolve or stabilize, whichever comes first. Patients will continue to be followed for PFS2 and OS, after discontinuing study drug (Section 10.3.3).
Sample 1
End of Treatment. The EOT visit will occur ≤30 days post-treatment discontinuation. After discontinuation of study treatment, patients will be followed for PFS approximately every 3 months after EOT visit until PD, death or initiation of the subsequent treatment (if a patient discontinues from the treatment due to reasons other than PD), and for survival every 3 months after end of treatment visit for 12 months or until withdrawal of consent, death, or the end of study (i.e., when the last patient in the study has been followed up on study treatment for at least 1 year or completed at least 6 months of survival follow-up period after their last dose of study treatment, has withdrawn consent, has died, or has been lost to follow-up, whichever occurs first). The duration of the study will be approximately 3 years.
Sample 1
End of Treatment. Visit 2 (Day 6)‌ With the exception of the CFRSD-CRISS administration and the blood and sputum samples for gallium and iron levels, the other Visit 2 procedures can be performed in any order in relation to the stop of the study drug infusion.
Sample 1
End of Treatment visit: three days after the last NI-0501 infusion The end of treatment visit should always be carried out 3 days (±1 day) after last NI-0501 infusion. This visit will include the following: Clinical assessment: ▪ Xxxxx xxxxx (blood pressure, oxygen saturation, heart and respiratory rate) and temperature ▪ Physical examination, including spleen and liver size (measure in cm from costal grill) as well as height and weight Procedure: ▪ ECG
Sample 1
End of Treatment. ‌ Subjects will receive therapy until independently-confirmed disease progression per irRECIST. In the absence of significant clinical deterioration requiring intervention, disease progression identified at Week 12 should be confirmed with a repeat scan ≥ 4 weeks later and the subject should continue treatment until independent confirmation of PD based on the confirmation scan. The End of Treatment visit will be completed within 14 days of independent confirmation of radiologic PD as assessed by irRECIST (§11.3) and prior to initiation of other anti-cancer therapy. • Complete PE, including xxxxx xxxxx (T, BP, RR, HR), ECOG performance status assessment and weight if not completed within the previous 14 days • Collect blood samples for the following analyses if not completed within the previous 14 days: — CBC — Serum chemistry • Collect urine for urinalysis if not completed within the previous 14 days • 12-lead ECG • Assess adverse events and update concomitant medications • Perform CT/MRI for subjects who have not had an imaging study within the previous 4 weeks
Sample 1
End of Treatment. Patients will continue to receive MIRV until they present with PD per RECIST 1.1, as assessed by study Investigator, unacceptable toxicity, withdraw consent, or death, whichever comes first, or until the Sponsor terminates the study. Study treatment and/or participation in the study may be discontinued at any time at the discretion of the Investigator. The following may be reasons for the Investigator to remove a patient from the study drug: • The patient suffers an intolerable AE • Noncompliance, including failure to appear at one or more study visits • The patient was erroneously included in the study The reason for treatment discontinuation must be captured in the clinical trial database. Any AEs experienced up to the point of discontinuation and 30 days thereafter must be documented. All serious adverse events (SAEs), and those AEs assessed by the Investigator as at least possibly related to study drug should continue to be followed until they resolve or stabilize, whichever comes first. Patients will continue to be followed for OS, after discontinuing study drug (Section 9.3.3).
Sample 1
AutoNDA by SimpleDocs

Related to End of Treatment

  • Equal Treatment No consideration shall be offered or paid to any person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered and paid to all the Subscribers and their permitted successors and assigns.

  • Confidential Treatment The parties hereto understand that any information or recommendation supplied by the Sub-Adviser in connection with the performance of its obligations hereunder is to be regarded as confidential and for use only by the Investment Manager, the Company or such persons the Investment Manager may designate in connection with the Fund. The parties also understand that any information supplied to the Sub-Adviser in connection with the performance of its obligations hereunder, particularly, but not limited to, any list of securities which may not be bought or sold for the Fund, is to be regarded as confidential and for use only by the Sub-Adviser in connection with its obligation to provide investment advice and other services to the Fund.

  • Treatment The Asset Representations Reviewer agrees to hold and treat Confidential Information given to it under this Agreement in confidence and under the terms and conditions of this Section 4.08, and will implement and maintain safeguards to further assure the confidentiality of the Confidential Information. The Confidential Information will not, without the prior consent of the Issuer and the Servicer, be disclosed or used by the Asset Representations Reviewer, or its officers, directors, employees, agents, representatives or affiliates, including legal counsel (collectively, the “Information Recipients”) other than for the purposes of performing Reviews of Review Receivables or performing its obligations under this Agreement. The Asset Representations Reviewer agrees that it will not, and will cause its Affiliates to not (i) purchase or sell securities issued by the Seller or its Affiliates or special purpose entities on the basis of Confidential Information or (ii) use the Confidential Information for the preparation of research reports, newsletters or other publications or similar communications.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!